Tag: Competition

Displaying 1341 - 1360 of 2071 results.

Pages

The Commission authorized a preliminary injunction to block Thoratec Corporation’s proposed $282 million acquisition of rival medical device maker HeartWare International, Inc., charging that the transaction would substantially reduce competition in the U.S. market for left...
The Federal Trade Commission has authorized a lawsuit to block Thoratec Corporation’s proposed $282 million acquisition of rival medical device maker HeartWare International, Inc., charging that the transaction would substantially reduce competition in the U.S. market for left ventricular devices...
The Commission issued an administrative complaint challenging Carilion Clinic’s 2008 acquisition of two competing outpatient clinics in the Roanoke, Virginia, area. The complaint alleges that Carilion’s acquisition of these outpatient centers eliminated competition for patients in...
The Federal Trade Commission has issued an administrative complaint challenging Carilion Clinic’s 2008 acquisition of two outpatient clinics in the Roanoke, Virginia, area. Prior to the acquisition, the Center for Advanced Imaging (CAI) and the Center for Surgical Excellence (CSE) had strong...
The Federal Trade Commission today told the Senate Subcommittee on Consumer Protection, Product Safety, and Insurance of the Committee on Commerce, Science & Transportation that competition and the agency’s antitrust enforcement improves health care in the United States in two ways – first, by...
The Federal Trade Commission today announced that it will modify a 2004 order against Aspen Technology, Inc. to restore competition in the U.S. markets for several engineering process simulation software products. The Commission’s action comes after Aspen Tech failed to divest certain assets in a...
The Federal Trade Commission today issued “Authorized Generics: An Interim Report,” which presents the first set of results from a study conducted to examine the short-term and long-term effects of “authorized generics” on competition in the prescription drug marketplace. An authorized generic...
In a speech today before the Center for American Progress in Washington, D.C., Federal Trade Commission Chairman Jon Leibowitz said that an internal FTC analysis projects that stopping collusive “pay-for-delay” settlements between brand and generic pharmaceutical firms would save consumers $3.5...
John C. Malone, CEO and Chairman of Discovery Holding Company, agreed to pay a $1.4 million civil penalty to settle Federal Trade Commission charges that he violated the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with acquisitions of Discovery shares in 2005...
John C. Malone, CEO and Chairman of Discovery Holding Company, has agreed to pay a $1.4 million civil penalty to settle Federal Trade Commission charges that he violated the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with acquisitions of Discovery shares in 2005 and 2008...
Testifying today on behalf of the Federal Trade Commission before the Subcommittee on Health of the U.S. House of Representatives Energy and Commerce Committee, Commissioner Pamela Jones Harbour presented the findings and recommendations of the FTC’s new Report, “Follow-on Biologic Drug...
The Federal Trade Commission today released a report entitled “Follow-on Biologic Drug Competition”which examines whether the price of biologic drugs – products manufactured using living tissues and microorganisms – could be reduced by competition from so-called “follow-on biologics” (FOBs). FOBs...
Following a public comment period, the Commission has granted, in part, a petition by Hexion LLC and Huntsman Corporation requesting that two FTC Orders related to their proposed merger be reopened and set aside. The agency has determined that the firms have satisfactorily shown that changed...
Following the Federal Trade Commission’s filing of a lawsuit to block the transaction, CSL Limited announced on June 8, 2009, that it will not proceed with its proposed $3.1 billion acquisition of Talecris Biotherapeutics. The FTC’s complaint charged that the deal would be illegal and would...
Federal Trade Commission Chairman Jon Leibowitz, Commissioner Pamela Jones Harbour, and Commissioner William E. Kovacic have issued a joint statement in response to the announcement by Endocare, Inc., that it has terminated its merger agreement with Galil Medical Ltd. during the agency’s ongoing...
Following a public comment period, the Commission has approved a final consent order in the matter of Reed Elsevier NV and ChoicePoint Inc. and authorized the staff to send letters to the commenters of record. The vote approving the final order was 4-0. (FTC File No. 081-0133; the staff contact is...
Alta Bates Medical Group, Inc., a 600-physician independent practice association serving the Berkeley and Oakland, California, area, settleed Commission charges that it violated federal antitrust law by fixing prices charged to health care insurers. The consent order prohibits Alta...
Alta Bates Medical Group, Inc. (Alta Bates), a 600-physician independent practice association serving the Berkeley and Oakland, California, area, has agreed to settle Federal Trade Commission charges that it violated federal antitrust law by fixing prices charged to health care insurers. A...

Pages